Poolbeg Pharma PLC
Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
By Elric Langton and Alex Langton | 17 January 2024
Elric has a financial interest in Poolbeg Pharma.
In the swirling maelstrom of the biotech sector, where the giddy highs of the 2020-21 speculative bonanza have given way to a starkly contrasting funding landscape, marked by soaring interest rates, burgeoning inflation, and a rather recalcitrant IPO bazaar, many a fledgeling firm finds itself in a bit of a pickle. Yet, amidst this somewhat bleak panorama, Poolbeg Pharma emerges as a beacon of resilience, unfazed by the financial squalls that beleaguered its contemporaries because it has no such funding concerns; indeed, we have heard the bold statement βwe will never need to raise funds from the market,β or similar sentiment multiple times from both Cathal Freil and Jerremy Skillingon, CEO.